Coya Therapeutics, Inc. Common Stock (COYA)vsNovartis AG ADR (NVS)
COYA
Coya Therapeutics, Inc. Common Stock
$4.38
-3.10%
HEALTHCARE · Cap: $106.03M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 706875% more annual revenue ($56.69B vs $8.02M). NVS leads profitability with a 22.5% profit margin vs -270.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
COYA
Avoid29
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.6%
Fair Value
$4.34
Current Price
$4.38
$0.04 premium
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 49.0% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : COYA
The strongest argument for COYA centers on Revenue Growth, Price/Book. Revenue growth of 49.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : COYA
The primary concerns for COYA are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
COYA profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
COYA carries more volatility with a beta of 0.60 — expect wider price swings.
COYA is growing revenue faster at 49.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 29/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coya Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?